Holen Sie sich die Stockscreener-App
127.08
0.06%
0.08
Schlusskurs vom Vortag:
$127.00
Offen:
$127.27
24-Stunden-Volumen:
1.44M
Relative Volume:
0.69
Marktkapitalisierung:
$13.50B
Einnahmen:
$612.78M
Nettoeinkommen (Verlust:
$-86.37M
KGV:
-146.07
EPS:
-0.87
Netto-Cashflow:
$-62.91M
1W Leistung:
-0.21%
1M Leistung:
+52.16%
6M Leistung:
+61.43%
1J Leistung:
+88.71%
1-Tages-Spanne:
$127.01
$127.27
1-Wochen-Bereich:
$126.91
$127.47
52-Wochen-Spanne:
$62.78
$128.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Firmenname
Intra Cellular Therapies Inc
Sektor
Telefon
(646) 440-9333
Adresse
135 ROUTE 202/206, BEDMINSTER, NY
Vergleichen Sie ITCI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
127.08 | 13.50B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-11 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-08-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-22 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Eingeleitet | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-10 | Eingeleitet | Goldman | Buy |
| 2020-02-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-31 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-12 | Eingeleitet | Jefferies | Buy |
| 2018-02-26 | Eingeleitet | JP Morgan | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-11-08 | Hochstufung | SunTrust | Hold → Buy |
| 2017-09-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-29 | Herabstufung | SunTrust | Buy → Neutral |
Alle ansehen
Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around? - The Motley Fool
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Raised by SG Americas Securities LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Trimmed by Moody Aldrich Partners LLC - MarketBeat
Canaccord cuts Intra-Cellular stock rating, raises target to $132 - MSN
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 - Marketscreener.com
R Squared Ltd Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN
Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Cantor Fitzgerald Estimates ITCI FY2025 Earnings - Defense World
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy - BioSpace
Intra-Cellular Therapies (NASDAQ:ITCI) Given "Sector Perform" Rating at Royal Bank of Canada - MarketBeat
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025 - Chemistry World
Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Johnson & Johnson acquires Intra-Cellular Therapies - Pf Media
Research Analysts Issue Forecasts for ITCI FY2025 Earnings - MarketBeat
RBC Capital cuts Intra-Cellular stock rating, hikes target to $132 - MSN
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSEENFN), Intra-Cellular Therapies, Inc. (NasdaqITCI), H&E Equipment Services, Inc. (NasdaqHEES), Shutterstock, Inc. (NYSE - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
Intra-Cellular Therapies Enters Merger Agreement with Johnson & Johnson - Defense World
Johnson & Johnson to acquire Intra-Cellular Therapies - Scientist Live
Avanza Fonder AB Buys New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - MSN
Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
J&J to buy Intra-Cellular Therapies for $14.6 billion - MSN
Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey
Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey
J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN
Johnson & Johnson pays $14.6 billion for mental health biopharma company - DOTmed HealthCare Business News
Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga
Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says GlobalData - Express Pharma
Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN
Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN
Finanzdaten der Intra Cellular Therapies Inc-Aktie (ITCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intra Cellular Therapies Inc-Aktie (ITCI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):